PPAR-γ: Therapeutic Potential for Multiple Sclerosis
2008
PPAR-γ: Therapeutic Potential for Multiple Sclerosis
publication
Evidence: moderate
Author Information
Author(s): Paul D. Drew, Xu Jihong, Michael K. Racke
Primary Institution: University of Arkansas for Medical Sciences
Hypothesis
PPAR-γ agonists may have therapeutic potential in the treatment of multiple sclerosis.
Conclusion
PPAR-γ agonists can limit pathology in animal models of multiple sclerosis and may be effective in treating the disease in humans.
Supporting Evidence
- PPAR-γ agonists can regulate immune function in glial cells.
- These agonists may protect neurons from neurotoxic agents.
- PPAR-γ agonists have been shown to modulate the production of proinflammatory cytokines.
- Studies suggest that PPAR-γ agonists may alter the viability and function of lymphocytes.
Takeaway
This study looks at how certain drugs can help treat multiple sclerosis by affecting immune responses in the body.
Methodology
The review discusses various studies on the effects of PPAR-γ agonists on immune responses and their potential therapeutic effects in multiple sclerosis.
Limitations
The review is based on existing studies and does not present new experimental data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website